Oramed Pharmaceuticals Inc. (ORMP)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman | 754.3k | -- | 1974 |
Mr. David Silberman CPA | CFO & Treasurer | 259.53k | -- | 1984 |
Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director | 503.95k | -- | 1940 |
Mr. Joshua Hexter | Chief Operating & Business Officer | 326.94k | -- | 1970 |
Oramed Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Corporate Governance
Recent Events
- Mar 19, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 06, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 23, 20248-K: Corporate Changes & Voting MattersSee Full Filing